Wire · regulatory
Human studies begin for hard-to-treat cancers. Treatment invented in Tri-Cities
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 August 2026 · Fusion42 review
RadioGel, a radionuclide therapy developed by Battelle at Pacific Northwest National Laboratory and commercialized by Vivos Inc., is entering human trials in the U.S. after earlier use in India and veterinary applications. The treatment delivers targeted radiation to hard-to-treat cancers, minimising damage to healthy tissue, and has shown promising results in early patients.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
FDA approval of RadioGel as a medical device clears a faster pathway for novel cancer treatments to enter the U.S. market, making it urgent for oncology-focused founders to engage with clinical and regulatory strategies now. The precedent signals a possible shortcut for therapies that precisely target tumours while avoiding collateral damage.
◆ Coverage
1 source · 2 Aug 2026
◆ Related on Wire
◆ Topics